BACKGROUND/AIMS: Smad7 is an inhibitory Smad of the transforming growth factor (TGF)-beta signaling pathway. To study resistance mechanisms to antiproliferating effect of TGF-beta in human multistep hepatocarcinogenesis, Smad7, Smad4, TGF-beta1 and TGF-beta receptor II were investigated. METHODOLOGY: Smad7 and Smad4 were evaluated in 15 low-grade dysplastic nodules (DNs), 9 high-grade DNs, 6 early hepatocellular carcinomas (eHCCs) and 41 advanced HCCs by immunohistochemistry and in 37 HCCs and corresponding non-HCCs with fresh tissue, the mRNAs of TGF-beta1 and TGF-beta receptor II were analyzed by RT-PCR. RESULTS: Smad7 immunoreactivity in tumor cells was found in 25 (61%) advanced HCCs, in contrast to none of DNs and eHCCs. Smad7 expression was significantly higher in advanced HCCs with increased TGF-beta1 or no decrease of TGF-beta receptor II compared to those of corresponding non-HCCs (p=0.044, p=0.027). Smad4 expression in stellate cells was present in 28 (68%) advanced HCCs, which was higher in smaller sized and better differentiated HCCs. CONCLUSIONS: Smad7, expressed in tumor cells, is considered to be one of resistance mechanisms to increased TGF-beta1 in late stage hepatocarcinogenesis, especially in advanced HCCs without reduced TGF-beta receptor II. Smad4, in stellate cells of HCCs, might be involved in the host resistance to hepatocarcinogenesis.
BACKGROUND/AIMS: Smad7 is an inhibitory Smad of the transforming growth factor (TGF)-beta signaling pathway. To study resistance mechanisms to antiproliferating effect of TGF-beta in human multistep hepatocarcinogenesis, Smad7, Smad4, TGF-beta1 and TGF-beta receptor II were investigated. METHODOLOGY:Smad7 and Smad4 were evaluated in 15 low-grade dysplastic nodules (DNs), 9 high-grade DNs, 6 early hepatocellular carcinomas (eHCCs) and 41 advanced HCCs by immunohistochemistry and in 37 HCCs and corresponding non-HCCs with fresh tissue, the mRNAs of TGF-beta1 and TGF-beta receptor II were analyzed by RT-PCR. RESULTS:Smad7 immunoreactivity in tumor cells was found in 25 (61%) advanced HCCs, in contrast to none of DNs and eHCCs. Smad7 expression was significantly higher in advanced HCCs with increased TGF-beta1 or no decrease of TGF-beta receptor II compared to those of corresponding non-HCCs (p=0.044, p=0.027). Smad4 expression in stellate cells was present in 28 (68%) advanced HCCs, which was higher in smaller sized and better differentiated HCCs. CONCLUSIONS:Smad7, expressed in tumor cells, is considered to be one of resistance mechanisms to increased TGF-beta1 in late stage hepatocarcinogenesis, especially in advanced HCCs without reduced TGF-beta receptor II. Smad4, in stellate cells of HCCs, might be involved in the host resistance to hepatocarcinogenesis.
Authors: Ji Yeon Baek; Shelli M Morris; Jean Campbell; Nelson Fausto; Matthew M Yeh; William M Grady Journal: Int J Cancer Date: 2010-09-01 Impact factor: 7.396
Authors: Alev Deli; Emanuel Kreidl; Stefan Santifaller; Barbara Trotter; Katja Seir; Walter Berger; Rolf Schulte-Hermann; Chantal Rodgarkia-Dara; Michael Grusch Journal: World J Gastroenterol Date: 2008-03-21 Impact factor: 5.742
Authors: K Kitisin; N Ganesan; Y Tang; W Jogunoori; E A Volpe; S S Kim; V Katuri; B Kallakury; M Pishvaian; C Albanese; J Mendelson; M Zasloff; A Rashid; T Fishbein; S R T Evans; A Sidawy; E P Reddy; B Mishra; L B Johnson; K Shetty; L Mishra Journal: Oncogene Date: 2007-06-04 Impact factor: 9.867
Authors: Haichuan Wang; Xinhua Song; Haotian Liao; Pan Wang; Yi Zhang; Li Che; Jie Zhang; Yi Zhou; Antonio Cigliano; Cindy Ament; Daphne Superville; Silvia Ribback; Melissa Reeves; Giovanni M Pes; Binyong Liang; Hong Wu; Matthias Evert; Diego F Calvisi; Yong Zeng; Xin Chen Journal: Hepatology Date: 2021-06-15 Impact factor: 17.298
Authors: Sharon Sheahan; Christopher O Bellamy; Donald R Dunbar; David J Harrison; Sandrine Prost Journal: BMC Cancer Date: 2007-11-19 Impact factor: 4.430